The main compounds studied include semaglutide, tirzepatide, retatrutide, and liraglutide
One of the main identified targets is the nitric oxide (NO) pathway, where the peptide acts as a modulator of NO synthesis via NO synthase (NOS) enzymes
[DOI] [PMC free article] [PubMed] [Google Scholar] 45.Wallner M, et al
Weight loss Available in NZ = Liraglutide high dose (Saxenda, daily injection) Self-funding needed ($500-600/month) Not available in NZ = Semaglutide (Ozempic, Wegovy) or Tirzepatide (Mounjaro), as of May 2023 Side effects, particularly upper gastrointestinal, are common with GLP-1 agonist initiation
Yes, certain medical conditions require extra caution with GLP-1 medications, and in some cases, these medications may not be appropriate